B8F.L Regulatory News (B8F)

Biofrontera - Result of Annual General Meeting

· Shareholders approve all resolutions

· Creation of new Authorized Capital and new Contingent Capital resolved

Leverkusen, Germany, 31 August 2015 - Biofrontera AG (FSE/AIM:B8F), the biopharmaceutical company focusing on sun-induced skin cancer, announces that all proposed resolutions were passed at the Annual General Meeting of the company held on Friday 28 August 2015, with a significant majority for each resolution. The shareholders of Biofrontera AG resolved the revocation of the existing Authorised Capital I and the creation of a new Authorised Capital I with a nominal amount of up to 11,786,921 shares by a majority of 98.8 %, as well as the creation of a new Contingent Capital by a majority of 98.9 %. This provides the company with the operational and strategic flexibility required to pursue its strategic goals. Further, the members of Biofrontera's Executive Board and Supervisory Board were discharged for the fiscal year 2014, the auditor for the company's annual financial statements was confirmed and a new stock option plan was approved.

Prof. Hermann Lübbert, Chief Executive Officer of Biofrontera AG, comments: "We are very pleased with the broad support of our shareholders who have also expressed their approval to Biofrontera's strategy going forward. This will support the company to pursue the next stage of its corporate development plans. On behalf of the entire Management Board I would like to express my gratitude to all shareholders for their support and confidence."

Further information can be found on the company's website at:

http://biofrontera.com/en/investors/hauptversammlung.html

Ends

Enquiries, please contact:

Background:

Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.